



HAL
open science

Cryptosporidiosis after treatment with fingolimod: a case report and pharmacovigilance review

M. Martinot, A. Abou-Bacar, M. Lamothe, M. Alt Tebacher, M. Mohseni Zadeh, F. Dalle, L. Favennec, D. Costa, J. Brunet, F. Sellal

► **To cite this version:**

M. Martinot, A. Abou-Bacar, M. Lamothe, M. Alt Tebacher, M. Mohseni Zadeh, et al.. Cryptosporidiosis after treatment with fingolimod: a case report and pharmacovigilance review. BMC Infectious Diseases, BioMed Central, 2020, 20, pp.257. 10.1186/s12879-020-04988-7 . hal-02955645

HAL Id: hal-02955645

<https://hal-normandie-univ.archives-ouvertes.fr/hal-02955645>

Submitted on 2 Oct 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

CASE REPORT

Open Access



Cryptosporidiosis after treatment with fingolimod: a case report and pharmacovigilance review

M. Martinot^{1*}, A. Abou-Bacar², M. Lamothe³, M. Alt Tebacher³, M. Mohseni Zadeh¹, F. Dalle⁴, L. Favennec^{5,6}, D. Costa^{5,6}, J. Brunet^{2,7} and F. Sellal⁸

Abstract

Background: *Cryptosporidium* sp. are common intracellular parasites responsible of severe diarrhea in T-cell-immunocompromised patients. We report the first case of a woman who contracted cryptosporidiosis after treatment with fingolimod, a drug labeled for multiple sclerosis and responsible for marked lymphopenia.

Case presentation: A 60-year-old woman was admitted for abdominal pain diarrhea and fever. The patient suffered from multiple sclerosis and had been treated with fingolimod from august 2017 to september 2018 time of occurrence of the first digestive symptoms. Stool culture was negative but parasitological examination was positive for *Cryptosporidium* sp. Blood biological examination profound lymphopenia of 240/mm³ [17 CD4/mm³ (7%) and 32 CD8/mm³ (14%)]. Fingolimod was stopped, and the patient was put on nitazoxanide 500 mg bid for 7 days. The diarrhea resolved and no relapse was observed. Six other cases were found in the Pharmacovigilance database.

Conclusion: Physicians should be aware of this association and screen for *Cryptosporidium* in cases of diarrhea in patients treated with fingolimod. Patients should be aware of this risk and advise to take appropriate measures to avoid such contamination.

Keywords: Fingolimod, Cryptosporidiosis, *Cryptosporidium*, Multiple sclerosis

Background

Fingolimod (Gilenya[®]) is a sphingosine-1-phosphate receptor modulator, labeled for relapsing/remitting multiple sclerosis, that causes a drastic reduction of lymphocytes in the peripheral blood [1]. Several infections, including bronchitis, nasopharyngitis, central nervous system herpesvirus infections, and more rarely, progressive multifocal leukoencephalopathy, Kaposi sarcoma, CNS toxoplasmosis or cryptococcosis, have been reported in patients treated with fingolimod [1–4]. We

report the first case of cryptosporidiosis in a patient treated with fingolimod.

Cryptosporidiosis is caused by *Cryptosporidium* sp., an intracellular protozoan parasite responsible for gastroenteritis in humans and animals worldwide. Human cases are commonly due to two species, *C. hominis* and *C. parvum*. *Cryptosporidium* sp. have a global distribution, and *Cryptosporidium* infections are probably underdiagnosed. Recent data have suggested that the prevalence of stools positive for *Cryptosporidium* sp. may reach 1% in high-income countries and 5–10% in low and middle income countries [5]. The illness is usually asymptomatic or results in mild self-limiting diarrhea in immunocompetent hosts, but it can result in

* Correspondence: martin.martinot@ch-colmar.fr

¹Service de Maladies Infectieuses et Tropicales. Hôpitaux Civils de Colmar, 39 avenue de la liberté, 68024 Colmar, France

Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

prolonged diarrhea (7–14 days), persistent diarrhea (> 14 days), or even life-threatening episodes in malnourished children or T-cell-immunocompromised patients [5–8]. Cryptosporidiosis has been reported as one of the three most frequent causes of death in children aged < 5 years [9]. In France between 2015 and 2017, 210 cases of cryptosporidiosis were reported in immunodeficient patients, mainly patients undergoing solid organ transplantation or HIV infected patients [8]. However no earlier report of cryptosporidiosis has been associated with immunocompromised state due to treatment with fingolimod.

Case presentation

We report the case of a 60-year-old woman who contracted cryptosporidiosis after treatment with fingolimod for multiple sclerosis. The patient was initially treated by interferon β , and due to underlying pathology progression, fingolimod was introduced in august 2017. The patient was still treated by fingolimod in september 2018 when she presented to our emergency ward for abdominal pain and fever. Blood analysis revealed a mild inflammatory syndrome [C-reactive protein (CRP) level, 75 mg/l (normal range 0-5 mg/l)]. Treatment with amoxicillin and clavulanic acid was initiated. Fever disappeared, but abdominal discomfort persisted, with occurrence of diarrhea 3 days later (5–10 stools/day). Stool culture was negative, including for *Clostridium difficile*, but parasitological examination was positive for *Cryptosporidium* spp. (multiplex gastrointestinal parasite panel PCR Becton-Dickinson BD max[®]). The patient was referred for an infectious disease consultation. At admission on September 27, 2018, she still had severe diarrhea

with more than seven stools a day and abdominal discomfort. Blood biological examination showed a CRP level that returned to normal (< 5 mg/l) with profound lymphopenia of 240/mm³ [17 CD4/mm³ (7%) and 32 CD8 /mm³ (14%), flow cytometry BD FACS Canto II]. Stool examination using a modified Ziehl–Neelsen staining method revealed the presence of *Cryptosporidium* oocysts (> 10 oocysts/slide, 10 mg stool sample/slide) (Fig. 1). The stool samples were sent to the French *Cryptosporidiosis* national reference center for molecular identification. DNA was extracted from the stool samples with a QIAamp power fecal DNA kit (Qiagen[®], Courtaboeuf, France). GP 60 genotyping according to the protocol described by Sulaiman et al. (PCR 1: AL3531 (5'-ATAGTCTCCGCTGTATTC-3') and AL3533 (5'-GAGATATATCTTGGTGCG-3'); PCR 2: AL3532 (5'-TCCGCTGTATTCTCAGCC-3') and LX0029 (5'-CGAACCACATTACAAATGAAGT-3')) revealed IbA10G2 *C. hominis* infection [10]. Fingolimod was stopped, and the patient was put on nitazoxanide 500 mg bid for 7 days [11]. The diarrhea resolved within 4 days, and the lymphopenia rised to 480/mm³ lymphocytes [102/mm³ CD4 (28%) and 56/mm³ CD8 (15%)]. A control parasitological examination of the stool performed 2 weeks later was negative.

Discussion and conclusion

Fingolimod acts as a functional antagonist of sphingosine-1-phosphate (SP1), a mediator involved in the egress of lymphocytes from lymphoid organs and their recirculation in peripheral compartments, including a subset of lymphocytes implicated in multiple sclerosis [1, 12]. Fingolimod is generally well tolerated, as




Fig. 1 *Cryptosporidium* oocysts from stool, stained with modified Ziehl–Neelsen acid-fast stain. 54x40mm (220 × 220 DPI)

trafficking of lymphocytes is altered, but not their numbers or functions [1]. The most common adverse effects are cardiovascular events (bradycardia and atrioventricular block) [1–3]. Lymphopenia is part of the mode of action; it quickly occurs after initiation of fingolimod and usually resolves within 45 to 90 days after drug cessation, although long-lasting lymphopenia has been described [1]. Treatment with fingolimod decreased the absolute number of lymphocytes and all subsets of peripheral circulating lymphocytes especially T helpers and B cells and in a lesser extent cytotoxic lymphocytes and NK. Among T cells, naïve and central memory T cells are the most affected [13]. This lymphopenia is usually well tolerated, but severe infections (mostly *Herpesviridae* infections) have been reported [1–4].

Cryptosporidium is a protozoan parasite of medical and veterinary importance that causes gastroenteritis in numerous hosts and has a worldwide distribution [5, 6]. *Cryptosporidium* spp. are a common cause of diarrhea in immunocompetent patients, but the severity is typically dependent on parasite load and host factors, ranging from asymptomatic carriage to life-threatening disease [14, 15]. The disease is most severe in T-cell-deficient patients, especially those with AIDS with CD4 count < 50/mm³ [7, 8], therefore the marked lymphopenia resulting from fingolimod treatment could be the source for more severe disease. Our patient presented with persistent diarrhea (> 14 days), a course usually encountered in such immunodeficient patients [11].

To the best of our knowledge, no cases of cryptosporidiosis associated with fingolimod have been reported in the published literature. However, we found 6 cases of cryptosporidiosis listed under fingolimod in the database Vigilyse International database (<https://www.who-umc.org/vigibase/vigilyze/>). There was 1 man and 5 women (mean age 42 years), among whom cryptosporidiosis occurred after a period of 7 months to 3 years following the introduction of fingolimod; a prolonged hospitalization was noted in 3 cases but no death was reported. Searching for *Cryptosporidium* sp. which is very small is very difficult in stools, and thus practically requires microscopic analysis with specific stains [16]. Consequently, *Cryptosporidium* oocysts are not systematically searched during standard parasitological examination by microscopy. However, detection of *Cryptosporidium* DNA by polymerase chain reaction (PCR) is more and more frequent and also more sensitive than microscopic detection. PCR usually take part of multiplex gastrointestinal parasite panels, which will probably improve the diagnosis of cryptosporidiosis, as in our case [7, 17, 18].

It is difficult to firmly state that fingolimod was responsible for the development of cryptosporidiosis in our patient, as the disease can occur in

immunocompetent patients. However, the time course of the diarrhea and the mode of action of fingolimod are in favor of a strong imputability between exposure to fingolimod and the development of cryptosporidiosis. Physicians should be aware of this association and screen for *Cryptosporidium* sp. in cases of diarrhea in patients treated with fingolimod. Patients should also be made aware of this risk and advised to take appropriate measures to avoid such contamination and exposure. Useful measures to help prevent and control cryptosporidiosis in immunocompromised persons can be found on the US CDC website https://www.cdc.gov/parasites/crypto/gen_info/prevent_ic.html (accessed: 10 March 2020).

Abbreviations

CNS: Central nervous system; CRP: C-reactive protein

Acknowledgements

Not applicable.

Authors' contributions

MM, MMZ and FS did the study design. ML and MAT performed the database review, AAB, FD, LF, DC and JB performed the parasitological analysis. MM wrote the manuscript. All authors have read and approved the manuscript.

Funding

No funding was received.

Availability of data and materials

The data that support the findings of this study are available from the corresponding author (MM) is available from the corresponding author upon reasonable request.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Informed written consent for the publication of the case report was obtained from the patient.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Service de Maladies Infectieuses et Tropicales. Hôpitaux Civils de Colmar, 39 avenue de la liberté, 68024 Colmar, France. ²Laboratoire de Parasitologie et de Mycologie Médicale, Plateau Technique de Microbiologie, Hôpitaux Universitaires de Strasbourg, 1 place de l'Hôpital, 67091 Strasbourg Cedex, France. ³Centre régional de pharmacovigilance Hôpitaux Universitaires de Strasbourg, 1 place de l'Hôpital, F-67091 Strasbourg, France. ⁴Dijon University hospital François Mitterand, Laboratoire de Parasitologie Mycologie, Dijon, France. ⁵University of Medicine Pharmacy Rouen EA ESCAPE 7510, Rouen, France. ⁶CNR LE Cryptosporidiosis, Santé Publique France, Rouen, France. ⁷Institut de Parasitologie et Pathologie Tropicale, EA 7292, Fédération de Médecine Translationnelle, Université de Strasbourg, 3 rue Koeberlé, 67000 Strasbourg, France. ⁸Service de Neurologie. Hôpitaux Civils de Colmar, 39 avenue de la liberté, 68024 Colmar, France.

Received: 18 July 2019 Accepted: 24 March 2020

Published online: 30 March 2020

References

1. Thomas K, Proschmann U, Ziemssen T. Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis. *Expert Opin Pharmacother.* 2017;18(15):1649–60.

2. Faissner S, Gold R. Efficacy and safety of the newer multiple sclerosis drugs approved since 2010. *CNS Drugs*. 2018;32(3):269–87.
3. Yoshii F, et al. Neurological safety of fingolimod: an updated review. *Clin Exp Neuroimmunol*. 2017;8(3):233–43.
4. Epstein DJ, Dunn J, Deresinski S. Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and Management. *Open Forum Infect Dis*. 2018;5(8):ofy174.
5. Checkley W, et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. *Lancet Infect Dis*. 2015;15(1):85–94.
6. Caccio SM, Chalmers RM. Human cryptosporidiosis in Europe. *Clin Microbiol Infect*. 2016;22(6):471–80.
7. Bouzid M, et al. Cryptosporidium pathogenicity and virulence. *Clin Microbiol Rev*. 2013;26(1):115–34.
8. Costa D, et al. Human cryptosporidiosis in immunodeficient patients in France (2015–2017). *Exp Parasitol*. 2018;192:108–12.
9. Collaborators, G.B.D.D.D. Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the global burden of disease study 2015. *Lancet Infect Dis*. 2017;17(9):909–48.
10. Sulaiman IM, et al. Unique endemicity of cryptosporidiosis in children in Kuwait. *J Clin Microbiol*. 2005;43(6):2805–9.
11. Pantenburg B, Cabada MM, White AC Jr. Treatment of cryptosporidiosis. *Expert Rev Anti-Infect Ther*. 2009;7(4):385–91.
12. Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-phosphate receptor modulators for the treatment of multiple sclerosis. *Neurotherapeutics*. 2017;14(4):859–73.
13. Hjorth M, Dandu N, Mellergard J. Treatment effects of fingolimod in multiple sclerosis: selective changes in peripheral blood lymphocyte subsets. *PLoS One*. 2020;15(2):e0228380.
14. Borad A, Ward H. Human immune responses in cryptosporidiosis. *Future Microbiol*. 2010;5(3):507–19.
15. Wang RJ, et al. Widespread occurrence of Cryptosporidium infections in patients with HIV/AIDS: epidemiology, clinical feature, diagnosis, and therapy. *Acta Trop*. 2018;187:257–63.
16. Khurana S, Chaudhary P. Laboratory diagnosis of cryptosporidiosis. *Trop Parasitol*. 2018;8(1):2–7.
17. Autier B, et al. Comparison of three commercial multiplex PCR assays for the diagnosis of intestinal protozoa. *Parasite*. 2018;25:48.
18. Morio F, et al. Assessment of the first commercial multiplex PCR kit (ParaGENIE Crypto-Micro Real-Time PCR) for the detection of *Cryptosporidium* spp., *Enterocytozoon bienersi*, and *Encephalitozoon intestinalis* from fecal samples. *Diagn Microbiol Infect Dis*. 2019;95(1):34–7.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

